体外診断 (IVD) の世界市場 (製品／サービス別、技術別、用途別、エンドユーザー別)：産業分析・成長予測 (2030年まで)

世界の体外診断 (IVD) の市場規模は、2019年には635億米ドル、2030年には1274億ドルと、6.6％のCAGRで拡大すると予想されています。市場の主な促進要因として、血液サンプルの汚染に関する規制強化の動きや、慢性疾患の発症率の上昇、献血者の増加、IVD技術の急速な進歩、教育機関・病院の増加、世界各国での医療費の増大などが挙げられます。地域別では、アジア太平洋諸国での大幅な市場成長が見込まれています。

当レポートでは、世界の体外診断 (IVD) の市場について分析し、技術の概略や背景事情、市場の基本構造や主な市場促進・抑制要因、市場規模の実績値・予測値 (今後11年間分)、製品／サービス別・技術別・用途別・エンドユーザー別・地域別の詳細動向、市場競争状態、主要企業のプロファイルなどを調査しております。

目次

第1章 分析の背景事情

第2章 分析方法

第3章 エグゼクティブサマリー

第4章 イントロダクション

• 市場区分の定義
  • 製品／サービス別
    • 試薬・キット
    • 診断装置
    • ソフトウェア・サービス
  • 技術別
    • 臨床化学
    • 免疫化学
    • 分子診断
    • 血液検査
    • その他
  • 用途別
    • 感染症
    • 糖尿病
    • 腫瘍
    • 心臓病
    • 腎疾患
    • 自己免疫疾患
    • その他
  • エンドユーザー別
    • 病院・診療所
    • POC (ポイントオブケア)
    • 研究・教育機関
• バリューチェーン分析
• 市場のダイナミクス
  • 市場動向
    • 新製品の承認と発売
    • 事業提携・契約の件数増加
  • 促進要因
    • 血液の安全性とサンプル汚染に関する規制
    • 慢性疾患の負担の急増
    • 献血者の増加
    • IVDの技術進歩
    • 医療費の増加
    • 病院・教育機関の増加
    • 市場予測に対する促進要因の影響分析
  • 抑制要因
    • 十分で安全なサンプル供給を維持する上での課題
    • ドナーの人口統計情報に対するデータの不安定性
    • IVD製品の費用対効果
    • 市場予測に対する抑制要因の影響分析
• ポーターのファイブフォース分析
• 新型コロナウイルス感染症 (COVID-19) の影響

第5章 世界市場：市場規模とその予測

• 製品／サービス別
• 技術別
  • 臨床化学
  • 免疫化学
  • 分子診断
  • 血液検査
• 用途別
• エンドユーザー別
• 地域別

第6章 北米市場：市場規模とその予測

• 製品／サービス別
• 技術別
• 用途別
• エンドユーザー別
• 国別
  • 米国市場
  • カナダ市場

第7章 欧州市場：市場規模とその予測

• 国別
  • ドイツ市場
  • フランス市場
  • イタリア市場
  • スペイン市場
  • 英国市場

第8章 アジア太平洋市場：市場規模とその予測

• 国別
  • 中国市場
  • 日本市場
  • インド市場

第9章 ラテンアメリカ市場：市場規模とその予測

• 国別
  • ブラジル市場
  • メキシコ市場

第10章 中東・アフリカ市場：市場規模とその予測

• 国別
  • サウジアラビア市場
  • 南アフリカ市場

第11章 競合情勢

• 主要企業の市場シェア
• 主要企業の戦略展開状況
  • 製品の発売・承認
  • 企業合併・買収 (M&A)
  • その他

第12章 企業プロファイル

• Thermo Fisher Scientific Inc.
  • 事業概要
  • 主力製品／サービス
  • 主な財務指標
• Danaher Corporation
• F. Hoffmann-La Roche Ltd.
• PerkinElmer Inc.
• Quidel Corporation
• OraSure Technologies Inc.
• Sysmex Corporation
• DIAGNOSTICA STAGO S.A.S
• Siemens AG
• Abbott Laboratories
• Becton, Dickinson and Company
• Hologic Inc.
• Sartorius Stedim Biotech S.A.
• Bio-Rad Laboratories Inc.
• bioMerieux S.A.
• Trinity Biotech plc
• Bio-Techne Corporation
• DiaSorin S.p.A.
• Ortho-Clinical Diagnostics Inc.
• Grifols S.A.

第13章 付録

LIST OF FIGURES

• FIG 1 RESEARCH SCOPE
• FIG 2 RESEARCH METHODOLOGY
• FIG 3 SPLIT OF PRIMARY AND SECONDARY RESEARCH
• FIG 4 BREAKDOWN OF PRIMARY RESEARCH, BY REGION
• FIG 5 BREAKDOWN OF PRIMARY RESEARCH, BY INDUSTRY PARTICIPANT
• FIG 6 BREAKDOWN OF PRIMARY RESEARCH, BY COMPANY TYPE
• FIG 7 DATA TRIANGULATION APPROACH
• FIG 8 GLOBAL IVD MARKET SUMMARY
• FIG 9 BARGAINING POWER OF BUYERS
• FIG 10 BARGAINING POWER OF SUPPLIERS
• FIG 11 INTENSITY OF RIVALRY
• FIG 12 THREAT OF NEW ENTRANTS
• FIG 13 THREAT OF SUBSTITUTES
• FIG 14 GLOBAL IVD MARKET SNAPSHOT (2019)
• FIG 15 GLOBAL IVD MARKET, BY OFFERING, $M (2014-2030)
• FIG 16 GLOBAL IVD MARKET, BY TECHNOLOGY, $M (2014-2030)
• FIG 17 GLOBAL IVD MARKET, BY APPLICATION, $M (2014-2030)
• FIG 18 GLOBAL IVD MARKET, BY END USER, $M (2014-2030)
• FIG 19 GLOBAL IVD MARKET, BY REGION, $M (2014-2030)
• FIG 20 NORTH AMERICA IVD MARKET SNAPSHOT
• FIG 21 NORTH AMERICA IVD MARKET, BY OFFERING, $M (2014-2030)
• FIG 22 NORTH AMERICA IVD MARKET, BY TECHNOLOGY, $M (2014-2030)
• FIG 23 NORTH AMERICA IVD MARKET, BY APPLICATION, $M (2014-2030)
• FIG 24 NORTH AMERICA IVD MARKET, BY END USER, $M (2014-2030)
• FIG 25 NORTH AMERICA IVD MARKET, BY COUNTRY, $M (2014-2030)
• FIG 26 EUROPE IVD MARKET SNAPSHOT
• FIG 27 EUROPE IVD MARKET, BY OFFERING, $M (2014-2030)
• FIG 28 EUROPE IVD MARKET, BY TECHNOLOGY, $M (2014-2030)
• FIG 29 EUROPE IVD MARKET, BY APPLICATION, $M (2014-2030)
• FIG 30 EUROPE IVD MARKET, BY END USER, $M (2014-2030)
• FIG 31 EUROPE IVD MARKET, BY COUNTRY, $M (2014-2030)
• FIG 32 APAC IVD MARKET SNAPSHOT
• FIG 33 APAC IVD MARKET, BY OFFERING, $M (2014-2030)
• FIG 34 APAC IVD MARKET, BY TECHNOLOGY, $M (2014-2030)
• FIG 35 APAC IVD MARKET, BY APPLICATION, $M (2014-2030)
• FIG 36 APAC IVD MARKET, BY END USER, $M (2014-2030)
• FIG 37 APAC IVD MARKET, BY COUNTRY, $M (2014-2030)
• FIG 38 LATAM IVD MARKET SNAPSHOT
• FIG 39 LATAM IVD MARKET, BY OFFERING, $M (2014-2030)
• FIG 40 LATAM IVD MARKET, BY TECHNOLOGY, $M (2014-2030)
• FIG 41 LATAM IVD MARKET, BY APPLICATION, $M (2014-2030)
• FIG 42 LATAM IVD MARKET, BY END USER, $M (2014-2030)
• FIG 43 LATAM IVD MARKET, BY COUNTRY, $M (2014-2030)
• FIG 44 MEA IVD MARKET SNAPSHOT
• FIG 45 MEA IVD MARKET, BY OFFERING, $M (2014-2030)
• FIG 46 MEA IVD MARKET, BY TECHNOLOGY, $M (2014-2030)
• FIG 47 MEA IVD MARKET, BY APPLICATION, $M (2014-2030)
• FIG 48 MEA IVD MARKET, BY END USER, $M (2014-2030)
• FIG 49 MEA IVD MARKET, BY COUNTRY, $M (2014-2030)
• FIG 50 GLOBAL IVD MARKET SHARE OF KEY PLAYERS, 2019
• FIG 51 THERMO FISHER SCIENTIFIC INC. - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
• FIG 52 DANAHER CORPORATION - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
• FIG 53 F. HOFFMANN-LA ROCHE LTD. - REVENUE SPLIT BY DIVISION AND GEOGRAPHY (2019)
• FIG 54 PERKINELMER INC. - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
• FIG 55 QUIDEL CORPORATION - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
• FIG 56 ORASURE TECHNOLOGIES INC. - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
• FIG 57 SYSMEX CORPORATION - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2020)
• FIG 58 SIEMENS AG - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
• FIG 59 ABBOTT LABORATORIES - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
• FIG 60 BECTON, DICKINSON AND COMPANY - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
• FIG 61 HOLOGIC INC. - REVENUE SPLIT BY PRODUCT SEGMENT AND GEOGRAPHY (2019)
• FIG 62 SARTORIUS STEDIM BIOTECH S.A. - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
• FIG 63 BIO-RAD LABORATORIES INC. - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
• FIG 64 BIOMERIEUX S.A. - REVENUE SPLIT BY APPLICATION AND GEOGRAPHY (2018)
• FIG 65 TRINITY BIOTECH PLC. - REVENUE SPLIT BY SEGMENT (2018)
• FIG 66 BIO-TECHNE CORPORATION - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
• FIG 67 DIASORIN S.P.A. - REVENUE SPLIT BY TECHNOLOGY AND GEOGRAPHY (2018)
• FIG 68 GRIFOLS S.A. - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)

Title:
In Vitro Diagnostic Market Research Report: By Offering (Reagents & Kits, Instruments, Software & Services), Technology (Clinical Chemistry, Immunochemistry, Molecular Diagnostics, Hematology, Microbiology), Application (Infectious Diseases, Diabetes, Oncology, Cardiology, Nephrology, Autoimmune Diseases), End User (Hospitals & Clinics, Point of Care, Laboratories, Research & Academic Institutes) - Global Industry Analysis and Growth Forecast to 2030.

The global in-vitro diagnostic (IVD) market reached a valuation of $63.5 billion in 2019 and is predicted to progress at a CAGR of 6.6% between 2020 and 2030. According to the estimates of P&S Intelligence, a market research firm based in India, the market would generate a revenue of $127.4 billion by 2030. The key factor driving the progress of the market is the rising enactment of strict regulations and policies in several countries regarding blood sample contamination.

Besides the aforementioned factor, the growing incidence of chronic diseases, the surging number of blood donors, rapid advancements and innovations in the IVD technology, the increasing number of academic institutions and hospitals, and soaring healthcare expenditure in various countries are also fueling the expansion of the in-vitro diagnostic market across the world. As per the International Diabetes Federation (IDF) Atlas 9th edition, 352 million people in the age group 20-64 were diagnosed with diabetes in 2019.

Furthermore, this number is predicted to grow to 486 million by 2045. As per the findings of the World Health Organization (WHO), cancer claimed as many as 9.6 million lives in 2018. The Joint United Nations Programme on HIV/AIDS (UNAIDS) found that 37.9 million people around the world suffered from HIV/AIDS in 2018. The high occurrence of these diseases is boosting the demand for IVD testing, which is, in turn, propelling the growth of the market.

Based on offering, the in-vitro diagnostic market is divided into software & services, instruments, and reagents & kits. Out of these, the reagents & kits category is predicted to dominate the market in the future years. The increasing number of IVD tests being performed all over the world, because of the ballooning prevalence of infectious and chronic diseases and the surging number of research activities, is driving the advancement of this category in the market in the forthcoming years.

Geographically, the in-vitro diagnostic market is predicted to exhibit the fastest growth in the Asia-Pacific (APAC) region in the upcoming years. This would be because of the existence of leading market players in the region and their focus on various strategic development activities in order to improve their market position. For example, according to Abbott Laboratories, in October 2019, the Australian Red Cross Blood Service signed a multi-year agreement for Alinity system, the organization's plasma and blood screening technology.

Hence, it can be said without any hesitation that the market would boom in the future years, primarily because of the increasing requirement for blood donations and the growing enactment of several strict policies regarding blood contamination in several countries around the world.

Table of Contents

Chapter 1. Research Background

• 1.1 Research Objectives
• 1.2 Market Definition
• 1.3 Research Scope
  • 1.3.1 Market Segmentation by Offering
  • 1.3.2 Market Segmentation by Technology
  • 1.3.3 Market Segmentation by Application
  • 1.3.4 Market Segmentation by End User
  • 1.3.5 Market Segmentation by Region
  • 1.3.6 Analysis Period
  • 1.3.7 Market Data Reporting Unit
    • 1.3.7.1 Value
• 1.4 Key Stakeholders

Chapter 2. Research Methodology

• 2.1 Secondary Research
• 2.2 Primary Research
  • 2.2.1 Breakdown of Primary Research Respondents
    • 2.2.1.1 By region
    • 2.2.1.2 By industry participant
    • 2.2.1.3 By company type
• 2.3 Market Size Estimation
• 2.4 Data Triangulation
• 2.5 Assumptions for the Study

Chapter 3. Executive Summary

Chapter 4. Introduction

• 4.1 Definition of Market Segments
  • 4.1.1 By Offering
    • 4.1.1.1 Reagents & kits
    • 4.1.1.2 Instruments
    • 4.1.1.3 Software & services
  • 4.1.2 By Technology
    • 4.1.2.1 Clinical chemistry
      • 4.1.2.1.1 Basic metabolic panel
      • 4.1.2.1.2 Lipid profile
      • 4.1.2.1.3 Liver profile
      • 4.1.2.1.4 Renal profile
      • 4.1.2.1.5 Thyroid function panel
      • 4.1.2.1.6 Others
    • 4.1.2.2 Immunochemistry
      • 4.1.2.2.1 ELISA
      • 4.1.2.2.2 RIA
      • 4.1.2.2.3 FIA
      • 4.1.2.2.4 CLIA
      • 4.1.2.2.5 ICA
      • 4.1.2.2.6 Others
    • 4.1.2.3 Molecular diagnostics
      • 4.1.2.3.1 Infectious diseases
      • 4.1.2.3.2 Genomics
      • 4.1.2.3.3 Blood donor screening
      • 4.1.2.3.4 Others
    • 4.1.2.4 Hematology
      • 4.1.2.4.1 CBC
      • 4.1.2.4.2 Cholesterol testing
      • 4.1.2.4.3 Blood glucose testing
      • 4.1.2.4.4 Hemoglobin testing
      • 4.1.2.4.5 Coagulation testing
      • 4.1.2.4.6 Others
    • 4.1.2.5 Others
  • 4.1.3 By Application
    • 4.1.3.1 Infectious diseases
    • 4.1.3.2 Diabetes
    • 4.1.3.3 Oncology
    • 4.1.3.4 Cardiology
    • 4.1.3.5 Nephrology
    • 4.1.3.6 Autoimmune diseases
    • 4.1.3.7 Others
  • 4.1.4 By End User
    • 4.1.4.1 Hospitals & clinics
    • 4.1.4.2 POC
    • 4.1.4.3 Research & academic institutes
• 4.2 Market Dynamics
  • 4.2.1 Trends
    • 4.2.1.1 Approval and launch of new products
    • 4.2.1.2 Increasing number of collaborations and agreements
  • 4.2.2 Drivers
    • 4.2.2.1 Regulations with respect to blood safety and sample contamination
    • 4.2.2.2 Surging burden of chronic diseases
    • 4.2.2.3 Increasing number of blood donors
    • 4.2.2.4 Advancements in IVD technology
    • 4.2.2.5 Increasing healthcare expenditure
    • 4.2.2.6 Increasing number of hospitals and academic institutes
    • 4.2.2.7 Impact analysis of drivers on the market forecast period
  • 4.2.3 Restraints
    • 4.2.3.1 Challenges in maintaining sufficient, safe sample supply
    • 4.2.3.2 Data insecurity over donors' demographic information
    • 4.2.3.3 Cost-ineffectiveness of IVD products
    • 4.2.3.4 Impact analysis of restraints on the market forecast
• 4.3 Porter's Five Forces Analysis
• 4.4 Impact of COVID-19

Chapter 5. Global Market Size and Forecast

• 5.1 By Offering
• 5.2 By Technology
  • 5.2.1 IVD Market for Clinical Chemistry, by Type
  • 5.2.2 IVD Market for Immunochemistry, by Type
  • 5.2.3 IVD Market for Molecular Diagnostics, by Type
  • 5.2.4 IVD Market for Hematology, by Type
• 5.3 By Application
• 5.4 By End User
• 5.5 By Region

Chapter 6. North America Market Size and Forecast

• 6.1 By Offering
• 6.2 By Technology
  • 6.2.1 IVD Market for Clinical Chemistry, by Type
  • 6.2.2 IVD Market for Immunochemistry, by Type
  • 6.2.3 IVD Market for Molecular Diagnostics, by Type
  • 6.2.4 IVD Market for Hematology, by Type
• 6.3 By Application
• 6.4 By End User
• 6.5 By Country
  • 6.5.1 U.S. Market Size and Forecast
    • 6.5.1.1 By offering
    • 6.5.1.2 By technology
      • 6.5.1.2.1 IVD market for clinical chemistry, by type
      • 6.5.1.2.2 IVD market for immunochemistry, by type
      • 6.5.1.2.3 IVD market for molecular diagnostics, by type
      • 6.5.1.2.4 IVD market for hematology, by type
    • 6.5.1.3 By application
    • 6.5.1.4 By end user
  • 6.5.2 Canada Market Size and Forecast
    • 6.5.2.1 By offering
    • 6.5.2.2 By technology
      • 6.5.2.2.1 IVD market for clinical chemistry, by type
      • 6.5.2.2.2 IVD market for immunochemistry, by type
      • 6.5.2.2.3 IVD market for molecular diagnostics, by type
      • 6.5.2.2.4 IVD market for hematology, by type
    • 6.5.2.3 By application
    • 6.5.2.4 By end user

Chapter 7. Europe Market Size and Forecast

• 7.1 By Offering
• 7.2 By Technology
  • 7.2.1 IVD Market for Clinical Chemistry, by Type
  • 7.2.2 IVD Market for Immunochemistry, by Type
  • 7.2.3 IVD Market for Molecular Diagnostics, by Type
  • 7.2.4 IVD Market for Hematology, by Type
• 7.3 By Application
• 7.4 By End User
• 7.5 By Country
  • 7.5.1 Germany Market Size and Forecast
    • 7.5.1.1 By offering
    • 7.5.1.2 By technology
      • 7.5.1.2.1 IVD market for clinical chemistry, by type
      • 7.5.1.2.2 IVD market for immunochemistry, by type
      • 7.5.1.2.3 IVD market for molecular diagnostics, by type
      • 7.5.1.2.4 IVD market for hematology, by type
    • 7.5.1.3 By application
    • 7.5.1.4 By end user
  • 7.5.2 France Market Size and Forecast
    • 7.5.2.1 By offering
    • 7.5.2.2 By technology
      • 7.5.2.2.1 IVD market for clinical chemistry, by type
      • 7.5.2.2.2 IVD market for immunochemistry, by type
      • 7.5.2.2.3 IVD market for molecular diagnostics, by type
      • 7.5.2.2.4 IVD market for hematology, by type
    • 7.5.2.3 By application
    • 7.5.2.4 By end user
  • 7.5.3 Italy Market Size and Forecast
    • 7.5.3.1 By offering
    • 7.5.3.2 By technology
      • 7.5.3.2.1 IVD market for clinical chemistry, by type
      • 7.5.3.2.2 IVD market for immunochemistry, by type
      • 7.5.3.2.3 IVD market for molecular diagnostics, by type
      • 7.5.3.2.4 IVD market for hematology, by type
    • 7.5.3.3 By application
    • 7.5.3.4 By end user
  • 7.5.4 Spain Market Size and Forecast
    • 7.5.4.1 By offering
    • 7.5.4.2 By technology
      • 7.5.4.2.1 IVD market for clinical chemistry, by type
      • 7.5.4.2.2 IVD market for immunochemistry, by type
      • 7.5.4.2.3 IVD market for molecular diagnostics, by type
      • 7.5.4.2.4 IVD market for hematology, by type
    • 7.5.4.3 By application
    • 7.5.4.4 By end user
  • 7.5.5 U.K. Market Size and Forecast
    • 7.5.5.1 By offering
    • 7.5.5.2 By technology
      • 7.5.5.2.1 IVD market for clinical chemistry, by type
      • 7.5.5.2.2 IVD market for immunochemistry, by type
      • 7.5.5.2.3 IVD market for molecular diagnostics, by type
      • 7.5.5.2.4 IVD market for hematology, by type
    • 7.5.5.3 By application
    • 7.5.5.4 By end user

Chapter 8. APAC Market Size and Forecast

• 8.1 By offering
• 8.2 By Technology
  • 8.2.1 IVD Market for Clinical Chemistry, by Type
  • 8.2.2 IVD Market for Immunochemistry, by Type
  • 8.2.3 IVD Market for Molecular Diagnostics, by Type
  • 8.2.4 IVD Market for Hematology, by Type
• 8.3 By Application
• 8.4 By End User
• 8.5 By Country
  • 8.5.1 China Market Size and Forecast
    • 8.5.1.1 By offering
    • 8.5.1.2 By technology
      • 8.5.1.2.1 IVD market for clinical chemistry, by type
      • 8.5.1.2.2 IVD market for immunochemistry, by type
      • 8.5.1.2.3 IVD market for molecular diagnostics, by type
      • 8.5.1.2.4 IVD market for hematology, by type
    • 8.5.1.3 By application
    • 8.5.1.4 By end user
  • 8.5.2 Japan Market Size and Forecast
    • 8.5.2.1 By offering
    • 8.5.2.2 By technology
      • 8.5.2.2.1 IVD market for clinical chemistry, by type
      • 8.5.2.2.2 IVD market for immunochemistry, by type
      • 8.5.2.2.3 IVD market for molecular diagnostics, by type
      • 8.5.2.2.4 IVD market for hematology, by type
    • 8.5.2.3 By application
    • 8.5.2.4 By end user
  • 8.5.3 India Market Size and Forecast
    • 8.5.3.1 By offering
    • 8.5.3.2 By technology
      • 8.5.3.2.1 IVD market for clinical chemistry, by type
      • 8.5.3.2.2 IVD market for immunochemistry, by type
      • 8.5.3.2.3 IVD market for molecular diagnostics, by type
      • 8.5.3.2.4 IVD market for hematology, by type
    • 8.5.3.3 By application
    • 8.5.3.4 By end user

Chapter 9. LATAM Market Size and Forecast

• 9.1 By offering
• 9.2 By Technology
  • 9.2.1 IVD Market for Clinical Chemistry, by Type
  • 9.2.2 IVD Market for Immunochemistry, by Type
  • 9.2.3 IVD Market for Molecular Diagnostics, by Type
  • 9.2.4 IVD Market for Hematology, by Type
• 9.3 By Application
• 9.4 By End User
• 9.5 By Country
  • 9.5.1 Brazil Market Size and Forecast
    • 9.5.1.1 By offering
    • 9.5.1.2 By technology
      • 9.5.1.2.1 IVD market for clinical chemistry, by type
      • 9.5.1.2.2 IVD market for immunochemistry, by type
      • 9.5.1.2.3 IVD market for molecular diagnostics, by type
      • 9.5.1.2.4 IVD market for hematology, by type
    • 9.5.1.3 By application
    • 9.5.1.4 By end user
  • 9.5.2 Mexico Market Size and Forecast
    • 9.5.2.1 By offering
    • 9.5.2.2 By technology
      • 9.5.2.2.1 IVD market for clinical chemistry, by type
      • 9.5.2.2.2 IVD market for immunochemistry, by type
      • 9.5.2.2.3 IVD market for molecular diagnostics, by type
      • 9.5.2.2.4 IVD market for hematology, by type
    • 9.5.2.3 By application
    • 9.5.2.4 By end user

Chapter 10. MEA Market Size and Forecast

• 10.1 By offering
• 10.2 By Technology
  • 10.2.1 IVD Market for Clinical Chemistry, by Type
  • 10.2.2 IVD Market for Immunochemistry, by Type
  • 10.2.3 IVD Market for Molecular Diagnostics, by Type
  • 10.2.4 IVD Market for Hematology, by Type
• 10.3 By Application
• 10.4 By End User
• 10.5 By Country
  • 10.5.1 Saudi Arabia Market Size and Forecast
    • 10.5.1.1 By offering
    • 10.5.1.2 By technology
      • 10.5.1.2.1 IVD market for clinical chemistry, by type
      • 10.5.1.2.2 IVD market for immunochemistry, by type
      • 10.5.1.2.3 IVD market for molecular diagnostics, by type
      • 10.5.1.2.4 IVD market for hematology, by type
    • 10.5.1.3 By application
    • 10.5.1.4 By end user
  • 10.5.2 South Africa Market Size and Forecast
    • 10.5.2.1 By offering
    • 10.5.2.2 By technology
      • 10.5.2.2.1 IVD market for clinical chemistry, by type
      • 10.5.2.2.2 IVD market for immunochemistry, by type
      • 10.5.2.2.3 IVD market for molecular diagnostics, by type
      • 10.5.2.2.4 IVD market for hematology, by type
    • 10.5.2.3 By application
    • 10.5.2.4 By end user

Chapter 11. Competitive Landscape

• 11.1 Global IVD Market Share of Key Players
• 11.2 Strategic Developments of Key Players
  • 11.2.1 Product Launches and Approvals
  • 11.2.2 Mergers and Acquisitions
  • 11.2.3 Other Developments

Chapter 12. Company Profiles

• 12.1 Thermo Fisher Scientific Inc.
  • 12.1.1 Business Overview
  • 12.1.2 Product and Service Offerings
  • 12.1.3 Key Financial Summary
• 12.2 Danaher Corporation
  • 12.2.1 Business Overview
  • 12.2.2 Product and Service Offerings
  • 12.2.3 Key Financial Summary
• 12.3 F. Hoffmann-La Roche Ltd.
  • 12.3.1 Business Overview
  • 12.3.2 Product and Service Offerings
  • 12.3.3 Key Financial Summary
• 12.4 PerkinElmer Inc.
  • 12.4.1 Business Overview
  • 12.4.2 Product and Service Offerings
  • 12.4.3 Key Financial Summary
• 12.5 Quidel Corporation
  • 12.5.1 Business Overview
  • 12.5.2 Product and Service Offerings
  • 12.5.3 Key Financial Summary
• 12.6 OraSure Technologies Inc.
  • 12.6.1 Business Overview
  • 12.6.2 Product and Service Offerings
  • 12.6.3 Key Financial Summary
• 12.7 Sysmex Corporation
  • 12.7.1 Business Overview
  • 12.7.2 Product and Service Offerings
  • 12.7.3 Key Financial Summary
• 12.8 DIAGNOSTICA STAGO S.A.S
  • 12.8.1 Business Overview
  • 12.8.2 Product and Service Offerings
• 12.9 Siemens AG
  • 12.9.1 Business Overview
  • 12.9.2 Product and Service Offerings
  • 12.9.3 Key Financial Summary
• 12.10 Abbott Laboratories
  • 12.10.1 Business Overview
  • 12.10.2 Product and Service Offerings
  • 12.10.3 Key Financial Summary
• 12.11 Becton, Dickinson and Company
  • 12.11.1 Business Overview
  • 12.11.2 Product and Service Offerings
  • 12.11.3 Key Financial Summary
• 12.12 Hologic Inc.
  • 12.12.1 Business Overview
  • 12.12.2 Product and Service Offerings
  • 12.12.3 Key Financial Summary
• 12.13 Sartorius Stedim Biotech S.A.
  • 12.13.1 Business Overview
  • 12.13.2 Product and Service Offerings
  • 12.13.3 Key Financial Summary
• 12.14 Bio-Rad Laboratories Inc.
  • 12.14.1 Business Overview
  • 12.14.2 Product and Service Offerings
  • 12.14.3 Key Financial Summary
• 12.15 bioMerieux S.A.
  • 12.15.1 Business Overview
  • 12.15.2 Product and Service Offerings
  • 12.15.3 Key Financial Summary

12.16 Trinity Biotech plc

• 12.16.1 Business Overview
• 12.16.2 Product and Service Offerings
• 12.16.3 Key Financial Summary

12.17 Bio-Techne Corporation

• 12.17.1 Business Overview
• 12.17.2 Product and Service Offerings
• 12.17.3 Key Financial Summary

12.18 DiaSorin S.p.A.

• 12.18.1 Business Overview
• 12.18.2 Product and Service Offerings
• 12.18.3 Key Financial Summary

12.19 Ortho-Clinical Diagnostics Inc.

• 12.19.1 Business Overview
• 12.19.2 Product and Service Offerings

12.20 Grifols S.A.

• 12.20.1 Business Overview
• 12.20.2 Product and Service Offerings
• 12.20.3 Key Financial Summary

Chapter 13. Appendix

• 13.1 Abbreviations
• 13.2 Sources and References
• 13.3 Related Reports